HS
RLMD icon

HighVista Strategies’s Relmada Therapeutics RLMD Stock Holding History

HighVista Strategies’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.08M Buy
+445,799
New +$3.12M 0.7% 45
2023
Q1 		– Sell
-26,299
Closed -$91.8K – 130
2022
Q4 		$91.8K Sell
26,299
-3,764
-13% -$33.1K 0.05% 105
2022
Q3 		$1.11M Buy
30,063
+570
+2% +$15.8K 0.64% 39
2022
Q2 		$560K Buy
29,493
+8,112
+38% +$177K 0.34% 72
2022
Q1 		$577K Buy
+21,381
New +$442K 0.37% 68
2021
Q1 		– Sell
-22,450
Closed -$720K – 137
2020
Q4 		$720K Buy
22,450
+9,885
+79% +$340K 0.46% 52
2020
Q3 		$473K Buy
12,565
+2,872
+30% +$111K 0.34% 55
2020
Q2 		$434K Buy
+9,693
New +$410K 0.36% 38

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighVista Strategies's RLMD Position: Q2 2026 in Review

HighVista Strategies opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 445,799 shares worth $3.08M. The stake represents 0.7% of the portfolio and ranks #45 among its holdings. This is a return to the name: HighVista Strategies previously reported a position in RLMD as recently as Q4 2022.

HighVista Strategies first reported a position in RLMD in Q2 2020 and has held it in 8 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • HighVista Strategies held 445,799 shares of Relmada Therapeutics worth $3.08M as of Q2 2026.
  • Relmada Therapeutics was a new HighVista Strategies position in Q2 2026.
  • Relmada Therapeutics made up 0.7% of HighVista Strategies's portfolio in Q2 2026, its #45 holding.
  • HighVista Strategies first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 8 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.